FI112169B - Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi - Google Patents

Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi Download PDF

Info

Publication number
FI112169B
FI112169B FI940674A FI940674A FI112169B FI 112169 B FI112169 B FI 112169B FI 940674 A FI940674 A FI 940674A FI 940674 A FI940674 A FI 940674A FI 112169 B FI112169 B FI 112169B
Authority
FI
Finland
Prior art keywords
injection
preservative
solution
human protein
process according
Prior art date
Application number
FI940674A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI940674A0 (fi
FI940674A (fi
Inventor
Fritz Demmer
Werner Gruber
Heinrich Woog
Gerhard Winter
Hans-Joerg Markl
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6438353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI112169(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI940674A0 publication Critical patent/FI940674A0/fi
Publication of FI940674A publication Critical patent/FI940674A/fi
Application granted granted Critical
Publication of FI112169B publication Critical patent/FI112169B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI940674A 1991-08-15 1994-02-14 Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi FI112169B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4126983 1991-08-15
DE4126983A DE4126983A1 (de) 1991-08-15 1991-08-15 Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
PCT/EP1992/001822 WO1993003744A1 (de) 1991-08-15 1992-08-10 Verfahren zur herstellung von humanproteinhaltigen, konservierten arzneimitteln für infusions- oder injektionszwecke
EP9201822 1992-08-10

Publications (3)

Publication Number Publication Date
FI940674A0 FI940674A0 (fi) 1994-02-14
FI940674A FI940674A (fi) 1994-02-14
FI112169B true FI112169B (fi) 2003-11-14

Family

ID=6438353

Family Applications (1)

Application Number Title Priority Date Filing Date
FI940674A FI112169B (fi) 1991-08-15 1994-02-14 Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi

Country Status (25)

Country Link
US (2) US5503827A (hu)
EP (2) EP0607156B1 (hu)
JP (1) JP3670660B2 (hu)
KR (1) KR100263282B1 (hu)
AT (1) ATE145138T1 (hu)
AU (2) AU678756B2 (hu)
CA (1) CA2115348C (hu)
CZ (1) CZ284853B6 (hu)
DE (2) DE4126983A1 (hu)
DK (1) DK0607156T3 (hu)
ES (1) ES2094923T3 (hu)
FI (1) FI112169B (hu)
GE (1) GEP19981289B (hu)
GR (1) GR3022037T3 (hu)
HU (1) HU227421B1 (hu)
IL (1) IL102775A (hu)
MX (1) MX9204636A (hu)
NO (1) NO309844B1 (hu)
RU (1) RU2091068C1 (hu)
SG (1) SG66226A1 (hu)
SK (1) SK281910B6 (hu)
TW (1) TW351677B (hu)
UA (1) UA26343C2 (hu)
WO (1) WO1993003744A1 (hu)
ZA (1) ZA926122B (hu)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
JP3541054B2 (ja) * 1994-04-21 2004-07-07 ユニ・チャーム株式会社 使い捨ておむつ
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
ES2248818T3 (es) * 1995-06-07 2006-03-16 Chiron Corporation Metodo de solubilizacion, purificacion y replegamiento de proteinas.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997026011A1 (en) * 1996-01-19 1997-07-24 Eli Lilly And Company Obesity protein formulations
AU1750997A (en) * 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
DE59804785D1 (de) * 1997-11-22 2002-08-22 Roche Diagnostics Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
KR100389726B1 (ko) * 1998-03-06 2003-06-27 쥬가이 세이야쿠 가부시키가이샤 안정한 과립구 콜로니-자극 인자 함유 제제
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
ATE310531T1 (de) 1998-08-07 2005-12-15 Stabilisierte pharmazeutische zusammensetzungen von hedgehog-proteinen und deren verwendung
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
PL203797B1 (pl) * 1999-04-09 2009-11-30 Ortho Mcneil Pharm Inc Kompozycje farmaceutyczne erytropoetyny
WO2001007086A1 (en) 1999-07-22 2001-02-01 Aventis Pharmaceuticals, Inc. Preserved pharmaceutical formulations
ES2248110T3 (es) * 1999-07-22 2006-03-16 Aventis Pharmaceuticals Inc. Formulaciones multidosis de eritropoyetina.
DK1129720T3 (da) 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
IL162796A0 (en) * 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
AU2003901515A0 (en) * 2003-04-02 2003-04-17 Norika Holdings Sterilisation process for pharmaceutical product
WO2004108152A1 (en) * 2003-06-10 2004-12-16 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
JP4522997B2 (ja) * 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2576473C (en) * 2004-08-24 2015-06-30 Daiichi Asubio Pharma Co., Ltd. Liquid preparation of physiologically active peptide
CA2618068C (en) * 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US8546328B2 (en) * 2007-08-27 2013-10-01 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP2010536906A (ja) 2007-08-27 2010-12-02 バイオジェネリクス アーゲー Ｇ−ｃｓｆの液体製剤
EP2219602A1 (en) * 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
CN101970010A (zh) * 2008-02-08 2011-02-09 拜奥吉耐里克斯股份公司 促卵泡激素的液体制剂
US8120369B2 (en) 2009-03-02 2012-02-21 Harris Corporation Dielectric characterization of bituminous froth
CN102548575A (zh) * 2009-09-25 2012-07-04 参天制药株式会社 滴眼剂
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2018187590A1 (en) * 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
KR20200143416A (ko) * 2018-04-09 2020-12-23 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 엑소좀을 사용하는 종양 유전자의 치료학적 표적화

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3106073A1 (de) * 1981-02-19 1982-08-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von sterilen zubereitungen hochviskoser loesungen und substanzen
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP3485184B2 (ja) * 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Also Published As

Publication number Publication date
SK281910B6 (sk) 2001-09-11
AU1633997A (en) 1997-05-22
NO940499L (no) 1994-02-14
IL102775A0 (en) 1993-01-31
AU710768B2 (en) 1999-09-30
EP0607156B1 (de) 1996-11-13
FI940674A0 (fi) 1994-02-14
DE4126983A1 (de) 1993-02-18
ZA926122B (en) 1994-02-14
WO1993003744A1 (de) 1993-03-04
NO309844B1 (no) 2001-04-09
HU9400416D0 (en) 1994-05-30
RU94016163A (ru) 1996-08-10
UA26343C2 (uk) 1999-08-30
SG66226A1 (en) 1999-07-20
CA2115348A1 (en) 1993-03-04
AU2409492A (en) 1993-03-16
HUT67379A (en) 1995-04-28
EP0528313A1 (de) 1993-02-24
US5503827A (en) 1996-04-02
JP3670660B2 (ja) 2005-07-13
CZ28794A3 (en) 1994-08-17
EP0607156A1 (de) 1994-07-27
MX9204636A (es) 1993-02-01
ATE145138T1 (de) 1996-11-15
FI940674A (fi) 1994-02-14
TW351677B (en) 1999-02-01
ES2094923T3 (es) 1997-02-01
GEP19981289B (en) 1998-05-01
DK0607156T3 (da) 1997-04-07
RU2091068C1 (ru) 1997-09-27
US6303113B1 (en) 2001-10-16
IL102775A (en) 1999-12-22
JPH06510031A (ja) 1994-11-10
CZ284853B6 (cs) 1999-03-17
NO940499D0 (no) 1994-02-14
HU227421B1 (en) 2011-05-30
GR3022037T3 (en) 1997-03-31
SK14894A3 (en) 1994-11-09
DE59207523D1 (de) 1996-12-19
CA2115348C (en) 2007-07-17
AU678756B2 (en) 1997-06-12
KR100263282B1 (ko) 2000-08-01
DE59207523C5 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
FI112169B (fi) Menetelmä ihmisproteiinipitoisten infuusio- tai injektointitarkoituksiin tarkoitettujen säilöttyjen lääkkeiden valmistamiseksi
EP0909564B1 (en) Erythropoietin solution preparation stabilized with amino acids
JP5941496B2 (ja) 成長ホルモン製剤
EP1180368B1 (en) Freeze dried hgf preparations
EP2501367B1 (en) Formulation for HGH and RHIGF-1 combination
JP3927248B2 (ja) Ｈｇｆ凍結乾燥製剤
JP3143470B2 (ja) ポリペプチド含有の皮下または筋肉内投与用医薬組成物
CA2792965A1 (en) Stable aqueous mia/cd-rap formulations
CN1802171B (zh) 不包含血清白蛋白的人红细胞生成素的稳定水溶液
KR880002037B1 (ko) 인터페론 조성물 및 이의 제조방법
US7468351B2 (en) Erythropoietin solution formulation

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired